Vancomycin eliminates gut deoxycholic acid, restoring ILC2 ER proteostasis and relieving colitis.
Background
Achieving remission in Ulcerative Colitis (UC) involves complex gut microbiota restructuring, yet the precise influence of microbial metabolites on immune-mediated tissue repair remains poorly understood. Current treatments often lack targeted mechanisms for addressing specific microbiota-host interactions that drive disease pathology. This study investigates how the gut microbiome and its metabolites, particularly deoxycholic acid (DCA), interfere with the crucial pro-healing functions of group 2 innate lymphoid cells (ILC2s), which are vital for mucosal repair.
Study Design
Researchers investigated the therapeutic effects of oral vancomycin in murine models of colitis, comparing its efficacy to clinical observations in UC patients. The study focused on identifying the mechanistic link between vancomycin, gut metabolites, and immune cell function. They analyzed the impact of vancomycin on gut microbiota composition and deoxycholic acid (DCA) levels. Further experiments explored how DCA directly affects ILC2s, including its binding to specific proteins and its influence on cellular processes like ER stress and protein folding. Pharmacological inhibition of PERK phosphorylation was also tested to assess its ability to restore ILC2 function.
Results
Oral vancomycin effectively alleviated colitis symptoms in murine models, mirroring its clinical efficacy in UC patients. Mechanistically, vancomycin's therapeutic effect was achieved by significantly reducing deoxycholic acid (DCA) levels in the gut. They discovered that DCA directly impairs mucosal repair driven by ILC2s by inducing ER stress. This occurs through DCA's direct binding to thioredoxin-related transmembrane protein 2 (TMX2). This interaction disrupts TMX2's role in protein folding, leading to an unresolved unfolded protein response via hyperactivation of PERK/eIF2α signaling. This signaling cascade then suppresses the production of pro-healing molecules by ILC2s. > Pharmacological inhibition of PERK phosphorylation successfully restored ILC2 function and accelerated colitis resolution, highlighting PERK as a potential therapeutic target.
Key Findings
- Oral vancomycin alleviates colitis symptoms in murine models by reducing gut deoxycholic acid (DCA).
- DCA impairs ILC2-driven mucosal repair by inducing ER stress.
- DCA directly binds to
TMX2, disrupting its protein folding role and activatingPERK/eIF2αsignaling. - Hyperactivation of
PERK/eIF2αsuppresses pro-healing molecule production by ILC2s. - Pharmacological inhibition of
PERK phosphorylationrestores ILC2 function and accelerates colitis resolution.
Why It Matters
This research uncovers a critical pathogenic axis involving the microbiota, deoxycholic acid (DCA), and ILC2s that obstructs mucosal healing in Ulcerative Colitis. For clinicians and biohackers, this suggests that targeting gut DCA levels, potentially through specific antibiotics like vancomycin or other microbiota-modulating strategies, could be a viable approach to promote UC remission. The identification of PERK/eIF2α signaling as a key mediator also opens avenues for novel therapeutic interventions, potentially through small molecule inhibitors, to restore ILC2 function. This work provides a mechanistic rationale for vancomycin's use in UC and points towards a more targeted, metabolite-driven strategy for managing inflammatory bowel disease.
vancomycin
deoxycholic-acid
ulcerative-colitis
ilc2s
er-stress
gut-microbiota